Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ADGRV1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ADGRV1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ADGRV1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
GO:001003827 | Esophagus | ESCC | response to metal ion | 208/8552 | 373/18723 | 5.02e-05 | 3.90e-04 | 208 |
GO:000961216 | Esophagus | ESCC | response to mechanical stimulus | 124/8552 | 216/18723 | 3.30e-04 | 1.94e-03 | 124 |
GO:007124117 | Esophagus | ESCC | cellular response to inorganic substance | 125/8552 | 226/18723 | 2.17e-03 | 9.67e-03 | 125 |
GO:00316478 | Lung | IAC | regulation of protein stability | 62/2061 | 298/18723 | 5.37e-07 | 3.32e-05 | 62 |
GO:00515924 | Lung | IAC | response to calcium ion | 31/2061 | 149/18723 | 3.47e-04 | 5.42e-03 | 31 |
GO:00100388 | Lung | IAC | response to metal ion | 61/2061 | 373/18723 | 1.02e-03 | 1.22e-02 | 61 |
GO:00096125 | Lung | IAC | response to mechanical stimulus | 39/2061 | 216/18723 | 1.29e-03 | 1.45e-02 | 39 |
GO:00018947 | Lung | IAC | tissue homeostasis | 46/2061 | 268/18723 | 1.50e-03 | 1.60e-02 | 46 |
GO:00602497 | Lung | IAC | anatomical structure homeostasis | 51/2061 | 314/18723 | 2.91e-03 | 2.61e-02 | 51 |
GO:003164713 | Lung | AIS | regulation of protein stability | 62/1849 | 298/18723 | 1.06e-08 | 1.63e-06 | 62 |
GO:005159212 | Lung | AIS | response to calcium ion | 30/1849 | 149/18723 | 1.18e-04 | 2.72e-03 | 30 |
GO:001003813 | Lung | AIS | response to metal ion | 57/1849 | 373/18723 | 5.80e-04 | 9.01e-03 | 57 |
GO:000189412 | Lung | AIS | tissue homeostasis | 41/1849 | 268/18723 | 3.13e-03 | 3.01e-02 | 41 |
GO:000189422 | Lung | AAH | tissue homeostasis | 21/613 | 268/18723 | 2.12e-04 | 1.16e-02 | 21 |
GO:006024912 | Lung | AAH | anatomical structure homeostasis | 23/613 | 314/18723 | 2.89e-04 | 1.45e-02 | 23 |
GO:003164723 | Lung | MIAC | regulation of protein stability | 36/967 | 298/18723 | 1.93e-06 | 2.42e-04 | 36 |
GO:001003823 | Lung | MIAC | response to metal ion | 36/967 | 373/18723 | 2.40e-04 | 8.06e-03 | 36 |
GO:005159222 | Lung | MIAC | response to calcium ion | 18/967 | 149/18723 | 6.87e-04 | 1.59e-02 | 18 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADGRV1 | SNV | Missense_Mutation | novel | c.697T>G | p.Leu233Val | p.L233V | Q8WXG9 | protein_coding | tolerated(0.53) | benign(0.038) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
ADGRV1 | SNV | Missense_Mutation | novel | c.887C>A | p.Ser296Tyr | p.S296Y | Q8WXG9 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
ADGRV1 | SNV | Missense_Mutation | novel | c.3161C>A | p.Pro1054His | p.P1054H | Q8WXG9 | protein_coding | deleterious(0.03) | probably_damaging(0.992) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
ADGRV1 | SNV | Missense_Mutation | novel | c.15049T>G | p.Ser5017Ala | p.S5017A | Q8WXG9 | protein_coding | tolerated(0.48) | benign(0) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
ADGRV1 | SNV | Missense_Mutation | novel | c.4832C>T | p.Thr1611Ile | p.T1611I | Q8WXG9 | protein_coding | tolerated(0.39) | possibly_damaging(0.733) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ADGRV1 | SNV | Missense_Mutation | | c.6058N>A | p.Asp2020Asn | p.D2020N | Q8WXG9 | protein_coding | tolerated(0.06) | benign(0.167) | TCGA-AX-A2IO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
ADGRV1 | SNV | Missense_Mutation | novel | c.6159N>C | p.Gln2053His | p.Q2053H | Q8WXG9 | protein_coding | deleterious(0.01) | probably_damaging(0.951) | TCGA-AX-A2IO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
ADGRV1 | SNV | Missense_Mutation | novel | c.779N>C | p.Asp260Ala | p.D260A | Q8WXG9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
ADGRV1 | SNV | Missense_Mutation | novel | c.1523N>G | p.Ile508Ser | p.I508S | Q8WXG9 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
ADGRV1 | SNV | Missense_Mutation | | c.2996N>T | p.Arg999Ile | p.R999I | Q8WXG9 | protein_coding | deleterious(0) | possibly_damaging(0.761) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |